Delving into the Latest Updates on Strontium Ranelate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Bivalos, Osseor, Ossum

+ [13]

Target

CaSR

Mechanism

CaSR agonists(Calcium sensing receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

OsteoporosisOsteoporosis, Postmenopausal

Originator Organization

Les Laboratoires Servier SAS

Active Organization-

Inactive Organization

Les Laboratoires Servier SAS

Drug Highest PhaseWithdrawn

First Approval Date

EU (20 Sep 2004),

Osteoporosis, PostmenopausalOsteoporosis

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC12H10N2O8SSr2

InChIKeyWJKLKWHUBHCSFS-UHFFFAOYSA-N

CAS Registry135459-87-9

View All Structures (2)

This study is being conducted with the aim of comparing the time to bone healing after surgery for fragility fractures of proximal femur between patients receiving strontium ranelate and placebo. Patients recruited are of 60 years of age and above. Bone healing will be assessed on clinical parameters when patient is able to ambulate full weight bearing without pain and on Xray images using RUSH score. Moreover Dexa scan will be performed pre-operatively and at 3 months postoperatively. The findings of this study will help in setting up guidelines for treatment of fragility proximal femur fractures in our population as there is still paucity of literature on effectiveness of strontium ranelate from our part of the world.

Start Date01 Nov 2021

Sponsor / Collaborator

AGA Khan University Hospital

NCT03937518

/ CompletedNot ApplicableIIT

Strontium Ranelate as New Modality in Treatment of Primary Knee Osteoarthritis

The present study was carried out on thirty patients with primary knee osteoarthritis. Patients were recruited from Rheumatology and Rehabilitation
Outpatient Clinic at Mansoura University Hospi Patients were divided into two groups:
Group 1: included 15 patients who received oral strontium ranelate and physiotherapy program. The age of the patients ranged from 50 to 62 years, they were 11 females and 4 males. Group 2: included 15 patients who received physiotherapy program. The age of the patients ranged from 50 to 62 years, they were 12 females and 3 males. Written consent was obtained from each participant sharing in the study. This study was approved by the institution research board of faculty of medicine, Mansoura University, code: MS/15.10.08. Inclusion

Start Date01 Jul 2018

Sponsor / Collaborator

Mansoura University

EUCTR2011-000708-17-AT

/ Not yet recruitingNot ApplicableIIT

A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with bisphosphonates

Start Date27 Aug 2013

Sponsor / Collaborator

Institut de Recherches Intern Servier

100 Clinical Results associated with Strontium Ranelate

Login to view more data

100 Translational Medicine associated with Strontium Ranelate

Login to view more data

100 Patents (Medical) associated with Strontium Ranelate

Login to view more data

826

Literatures (Medical) associated with Strontium Ranelate

01 Jan 2025·Osteoarthritis and Cartilage

Osteoarthritis year in review 2024: Imaging

Review

Author: Hayashi, Daichi ; Guermazi, Ali ; Roemer, Frank W. ; Roemer, Frank W

OBJECTIVETo review recent literature evidence describing imaging of osteoarthritis (OA) and to identify the current trends in research on OA imaging.METHODThis is a narrative review of publications in English, published between April, 2023, and March, 2024. A Pubmed search was conducted using the following search terms: osteoarthritis/OA, radiography, ultrasound/US, computed tomography/CT, magnetic resonance imaging/MRI, DXA/DEXA, and artificial intelligence/AI/deep learning. Most publications focus on OA imaging in the knee and hip. Imaging of OA in other joints and OA imaging with artificial intelligence (AI) are also reviewed.RESULTSCompared to the same period last year (April 2022 - March 2023), there has been no significant change in the number of publications utilizing CT, MRI, and AI. A notable reduction in the number of OA research papers using radiography and ultrasound is noted. There were several observational studies focusing on imaging of knee OA, such as the Multicenter Osteoarthritis Study, Rotterdam Study, Strontium ranelate efficacy in knee OA (SEKOIA) study, and the Osteoarthritis Initiative FNIH Biomarker study. Hip OA observational studies included, but not limited to, Cohort Hip and Cohort Knee study and UK Biobank study. Studies on emerging applications of AI in OA imaging were also covered. A small number of OA clinical trials were published with a focus on imaging-based outcomes.CONCLUSIONMRI-based OA imaging research continues to play an important role compared to other modalities. Usage of various AI tools as an adjunct to human assessment is increasingly applied in OA imaging research.

01 Jan 2025·Bone

Multiple vertebral fractures after antiosteoporotic medications discontinuation: A comparative study to evaluate the potential rebound effect of denosumab

Article

Author: Martín-Pérez, Mar ; Martín-Merino, Elisa ; García-Poza, Patricia ; Mar, Martín-Pérez ; Beatriz, Sánchez-Delgado ; Sánchez-Delgado, Beatriz ; Elisa, Martín-Merino ; López-Álvarez, Sergio ; Patricia, García-Poza

BACKGROUNDDiscontinuation of anti-osteoporotic medications (AOM), except for bisphosphonates (BP), is not favorable for the bone, being especially negative for Prolia® (60 mg denosumab-DMAb). DMAb withdrawal leads to a rapid and significant increase in bone turnover markers, and to an important loss in bone mineral density, which has been associated with an increased risk of multiple vertebral fractures (MVF).OBJECTIVETo assess the risk of MVF (≥2 VF) recorded at the same time) after discontinuation of different AOM.METHODSA case-control analysis nested in a cohort of new users of DMAb, BP, Teriparatide (TPTD), Strontium Ranelate (SrRan), or selective estrogen receptor modulators (SERM), aged ≥18 years from 2011 to 2018 with ≥1 year of prior available data, was performed using the Pharmacoepidemiological Research Database for the Public Health System (BIFAP) in Spain. Cases were first MVF recorded after AOM initiation (index date). Up to 4 controls per case, matched on index date, age, sex, and location, were randomly selected among non-cases from the cohort. Adjusted conditional OR (AOR) and 95 % CI: between discontinuation of a given AOM (supply of the last prescription ended >90 days before the index date) and occurrence of MVF was assessed compared with their current use and alternatively, with discontinuation of BP, among individuals who did not switch therapy in the study.RESULTSA total of 532 incident cases of MVF were identified and matched to 2121 controls (86 % women; median age 73 years). AOR of MVF after DMAb discontinuation was 2.82 (1.73-4.60) compared with DMAb current use. No risk was seen for the other AOM. The AOR was highest between 3 and 9 months after discontinuation of denosumab (8.58; 3.98-18.48) and after >1 year of cumulative use (5- and 11-times increased risk when discontinuing after 1-2 years and 2-5 years of use, respectively). Compared with BP discontinuers, discontinuation of DMAb (2.73, 1.66-4.50), TPTD (2.06, 1.09-3.88) and SrRan (1.93, 1.23-3.05) showed an increased risk of MVF; current use of DMAb showed no protective effect (1.44; 0.95-2.17).CONCLUSIONSDiscontinuation of DMAb was associated with an immediate increased risk of MVF, especially after longest treatments compared with patients who continued therapy or discontinued BP. Although there were increased risks after discontinuation of other AOM in comparison with first- line therapy (BP), these were not found when the reference was current users. Confounding by indication cannot be discarded. Larger studies should investigate reasons for discontinuation and preventive retreatment options.

01 Dec 2024·International Journal of Biological Macromolecules

Repairing effect of magnesium oxychloride cement modified by γ-polyglutamic acid and chitosan in osteoporotic bone defect

Article

Author: Guan, Yijia ; Yang, Yue ; Feng, Jinlun ; Zhang, Yanru ; Guo, Wenjie ; Ma, Tingting ; Liao, Jianguo ; Chen, Junying

Magnesium oxychloride cement (MOC) has the advantage of high early strength. However, it has the defect of poor water resistance. Considering this performance, we use γ-polyglutamic acid (γ-PGA) and chitosan (CS) to modify MOC. The effects of γ-PGA and CS such as strength, in vitro degradation and in vitro bioactivity of MOC were studied. Based on the preparation of γ-PGA and CS modified MOC (γ-PGA/CS-MOC) composite bone cement, the strontium ranelate (SrR) was loaded on. The results showed that the softening coefficient of γ-PGA/3 wt.% CS-MOC after soaking in SBF for 28 d reached 0.48, while that of control group (without CS and γ-PGA) was only 0.35; Cell experiments indicated that SrR could promote differentiation into osteoblasts. After the γ-PGA/CS-MOC composite bone cement containing SrR was implanted into the osteoporotic bone defect for 12 w, it was found that the material was gradually absorbed and the new bone tissue grew. The results showed that SrR/γ-PGA/CS-MOC composite bone cement had a potential application prospect in the repair of osteoporotic bone defects.

1

News (Medical) associated with Strontium Ranelate

07 Dec 2018

·www.bioportfolio.com

Human medicines European public assessment report (EPAR): Osseor, strontium ranelate, Osteoporosis, Postmenopausal, Date of authorisation: 20/09/2004, Revision: 19, Status: Authorised

This article has expired, however you can still download the PDF. Preview: Human medicines European public assessment report (EPAR): Osseor, strontium ranelate, Osteoporosis, Postmenopausal, Date of authorisation: 20/09/2004, Revision: 19, Status: Authorised...

100 Deals associated with Strontium Ranelate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08468	Strontium Ranelate	M05BX03	DB09267

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCO_IOF_ESCEO2018	Phase 3	Osteoporosis	83	Strontium ranelate 2g	rzfgfwgjpx(lwxnkzlthi) = evtxeqnimr cqzqoeswaw (ynystnduol, 0.098)	Negative	27 Jul 2018
				Placebo	rzfgfwgjpx(lwxnkzlthi) = lvwbeqcdxc cqzqoeswaw (ynystnduol, 0.085)
WCO_IOF_ESCEO2015	Not Applicable	serum 25(OH)D	108	Strontium Ranelate	uvqopzwmwe(kdyxetlugl) = iowmlxsnvb bsbkmsvmae (kmqnrxdrjz ) View more	Positive	17 Apr 2015
WCO_IOF_ESCEO2015	Not Applicable	Complex Regional Pain Syndromes	3	Strontium ranelate 2g daily	(hawbjzfigk) = livrfoujcz cqxhsdslre (bjckhptcwf ) View more	Positive	17 Apr 2015
WCO_IOF_ESCEO2015	Not Applicable	Osteoporosis	-	Strontium ranelate 2g/day	opzcdksckb(jbtxubyxks) = We documented 54 and 60 adverse events (AEs) in groups A and B respectively with no differences regarding thrombosis or cardiovascular events nqpncflvfu (gymkahenzh ) View more	Positive	17 Apr 2015
				No specific therapy
WCO_IOF_ESCEO2015	Not Applicable	bone specific alkaline phosphatase \| IGF-1 \| sclerostin ... View more	24	Strontium Ranelate 2g	bdhltzofgo(govbscytzo) = wuuiwwtreb welybitdbe (mvrfuwsbhe ) View more	-	17 Apr 2015
				Placebo	bdhltzofgo(govbscytzo) = jktccrbbht welybitdbe (mvrfuwsbhe ) View more
ISRCTN41323372 (Pubmed \| Rheumatology (Oxford))	Phase 3	Osteoarthritis, Knee	-	Strontium ranelate 2 g/day	vsdaolviim(afkfannfnq) = vkdgewaxrw nygoapillx (tfxofisuzu ) View more	-	01 Aug 2014
				Placebo	vsdaolviim(afkfannfnq) = snkzdqkltj nygoapillx (tfxofisuzu ) View more
EULAR2014	Not Applicable	Osteoporosis	134	Alfacalcidol	eaxinuartf(oalfliiucr) = zkgyvsgtoe nmvhecaywy (fvpwnlndgt )	-	11 Jun 2014
				Calcitonin	(ljcxwmpzwl) = oimxiycjis lkdjyxwucs (wyealfuhjr ) View more
SEKOIA (EULAR2014)	Not Applicable	Bone Marrow Diseases \| Osteoarthritis, Knee	330	Strontium ranelate 2 g/day	kkghgbihzu(pswcxfgycp) = ximhbxiola kihgngaofe (clwjmnqwql, 5.79) View more	-	11 Jun 2014
				Placebo	kkghgbihzu(pswcxfgycp) = hpopvafdwv kihgngaofe (clwjmnqwql, 8.74) View more
WCO_IOF_ESCEO2014	Phase 3	-	22	Strontium Ranelate 2g/day	(qnjgzmwxlq) = urinksdxkq brnxnnrmae (tuagxdnwrb )	Positive	02 Apr 2014
WCO_IOF_ESCEO2014	Not Applicable	Fractures, Ununited	8	Strontium ranelate 2g/day	awjwmvkhfj(reqgqnwxcj) = beginning of consolidation or early healing of the nonunion in 05 patients kuocnsdcqt (bdguoteioz ) View more	Positive	02 Apr 2014